Perseus Proteomics Past Earnings Performance
Past criteria checks 0/6
Perseus Proteomics's earnings have been declining at an average annual rate of -22.3%, while the Biotechs industry saw earnings growing at 18.4% annually. Revenues have been declining at an average rate of 16.6% per year.
Key information
-22.3%
Earnings growth rate
-7.0%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | -16.6% |
| Return on equity | -79.0% |
| Net Margin | -1,104.0% |
| Next Earnings Update | 14 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Perseus Proteomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 100 | -1,104 | 366 | 616 |
| 31 Dec 23 | 96 | -1,123 | 353 | 644 |
| 30 Sep 23 | 97 | -1,056 | 339 | 583 |
| 30 Jun 23 | 93 | -1,008 | 328 | 533 |
| 31 Mar 23 | 94 | -786 | 290 | 494 |
| 31 Dec 22 | 91 | -768 | 272 | 402 |
| 30 Sep 22 | 89 | -688 | 247 | 368 |
| 30 Jun 22 | 81 | -658 | 231 | 357 |
| 31 Mar 22 | 71 | -599 | 231 | 308 |
| 31 Dec 21 | 66 | -518 | 217 | 328 |
| 31 Mar 21 | 67 | -413 | 162 | 313 |
| 31 Dec 20 | 74 | -420 | 881 | -397 |
| 31 Mar 20 | 85 | -841 | 891 | 0 |
| 31 Mar 19 | 275 | -163 | 401 | 0 |
| 31 Mar 18 | 303 | -178 | 256 | 0 |
Quality Earnings: 4882 is currently unprofitable.
Growing Profit Margin: 4882 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4882 is unprofitable, and losses have increased over the past 5 years at a rate of 22.3% per year.
Accelerating Growth: Unable to compare 4882's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4882 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-53.7%).
Return on Equity
High ROE: 4882 has a negative Return on Equity (-78.97%), as it is currently unprofitable.